• Patients 30 years of age or older.
• Provision of signed and dated informed consent form.
• Diagnosis of multiple myeloma requiring therapy or relapsed multiple myeloma requiring change in therapy.
• Stated willingness to comply with all study procedures and availability for the duration of the study.
• Non-pediatric patient.

• Pediatric patient.
• Have known metallic implants that preclude MR scanning.
• Pregnant (a urine pregnancy test will be given at no cost to the patient).

• Adult, age ≥ 18 years old.
• Patients with active disease of intrahepatic, perihilar, distal CCA with histologic confirmation.
• Patients whose clinical provider orders cancer tissue mutation profiling test for clinical care.

• Females who are pregnant or attempting to become pregnant.
• Patient with significant anemia (Hemoglobin <7g/dL).

• Phenotypic criteria pointing to a genetically determined neuromuscular disease.
• Living and deceased subjects will be included.

• None.

• Male or female.
• Age ≥ 18 years.
• Healthy volunteers
  or patients already scheduled for a MR-guided procedure.

• Individuals < 18 years of age.
• Pregnant women.

• Age 18 years old and above.
• Diagnosis of prolactinoma.
• Ability to provide informed consent.

• None.

• Type 1 diabetes diagnosed clinically.
• Willing to perform study procedures and provide data for at least 10 days.

• Pregnant.

• Idiopathic Scoliosis (as diagnosed by the surgeon).
• Patients above 10 years old at the time of recruitment.
• Spina bifida occulta with no neurological signs and otherwise normal.
• Curves ranging between 11º and 40º of Cobb angle measurement and
  •Risser 0 or 1, as measured on a standing postero-anterior digital radiograph of the spine. 
• All single thoracic, thoraco-lumbar, lumbar, double major and triple major curves will be included in the study.

• Previous thoracic, pelvis or spine surgery as they may be co-factors in scoliosis initiation.
• Congenital scoliosis,
  •MRI abnormalities (including > 4mm of Syrinx and/or Chiari malformation).
• Syndromic scoliosis (associated with Marfan's or other genetic syndromes).
• Neuromuscular scoliosis.
• Developmental delay. 
• Spinal asymmetry. 
• Symptomatic spondylolisthesis. 
• Leg length discrepancy longer than 1 cm. 
• Unable or unwilling to firmly commit to returning for required follow-up visits.

• Adult male or female between 18 and 65 years of age.
• Adult male or female who is scheduled to receive a knee MRI at our facility. 

• Prior history of knee surgery.
• Inability to WB
• MRI incompatibility (e.g., presence of ferromagnetic implants, claustrophobia, etc.). 

• Patients had to be seen by a health care provider at least once at the Family Medicine and Primary Care Internal Medicine clinics of Mayo Clinic in Rochester, MN or the Mayo Clinic Health System during the study time. 
• Patients had to be empaneled to a primary care provider.
• Ability to give informed consent.
• Ability to read and speak the English language.
• Age 65 or older.

• Patients that had not to be seen by a health care provider during the study time.
• Any participant who refused medical record review.
• Incarcerated individuals.
• Hospice enrollment.
• Memory Care residents.
• Major Neurocognitive disorder (severe and moderate dementia).

• Fifteen women with GDM and 15 women without GDM will be recruited through the Mayo Clinic Obstetric Practice in Rochester, Minnesota in the third trimester of pregnancy.
• The screening visit will be scheduled from 2-12 weeks postpartum.
• Gestational diabetes will be diagnosed based on Carpenter and Coustan criteria when at least two of the following four plasma glucose concentrations [measured fasting and 1h, 2h and 3h during 100g oral glucose tolerance testing)(OGTT)] are met or exceeded:
  • fasting 95mg/dL (5.3mmol/L);
  • 1h 180mg/dL (10.0mmol/L);
  • 2h 155mg/dL (8.6mmol/L); and
  • 3h 140mg/dL (7.8mmol/L).
• Women will be characterized as having normal glucose tolerance if they do not meet or exceed two or more of the aforementioned values on OGTT. These women will have previously failed a 50g glucose challenge [1 hr glucose >= 140mg/dL (7.8mmol/L).
• We will also characterize women as having normal glucose metabolism if they passed a 50g glucose challenge in pregnancy [1 hr glucose <140mg/dL (7.8mmol/L)] and did not proceed to further glucose testing during the pregnancy.

• Women < 20 years of age or > 40 years of age will not be studied to minimize the potential confounding effects of extremes of age on glucose absorption and metabolism.
• Known active systemic illness.
• Women in which the index pregnancy was a multiple pregnancy.
• Women with an HbA1c of ≥ 5.7% (39mmol/mol) in early pregnancy or a history of diabetes.
• Prior therapy with an anti-diabetic medication, or a medication that could affect glucose metabolism.
• History of abdominal surgery (other than appendectomy, cholecystectomy or tubal ligation).

• Patients with clinically indicated MRI PDFF for liver imaging.
• Age greater than 18 years old.

Exclusion Criteria:

• Age under 18 years old.
• Vulnerable subjects such as prisoners and adults lacking capacity to consent.
• Patient with liver iron overload which may confound PDFF measurements.

• Any patient undergoing surgery or biopsy for malignancy in the kidney, bladder, prostate.
• Any patient undergoing resection or biopsy of tumor recurrence after surgery for malignancy in the kidney, bladder, prostate.
• Any patient undergoing resection or biopsy of tumor metastatic site after surgery for malignancy in the kidney, bladder, prostate.

• Inability to provide consent.
• Specimen and data related to this pilot study will be retained for future use in case we wish to perform further related studies and include these pilot patients in ensuing analyses. In that case, re-consent of patients will be required when they turn 18.   

• Patients from both genders and all ethnic backgrounds will be allowed with no reservation.

• Patients who do not consent to the study will be excluded despite being sequential.

• Displaced 3- and 4-part proximal humerus fractures.
• Age ≥ 65 years old and < 90 years old.

• < 65 years old or ≥ 90 years old.
• Medical comorbidities precluding surgical treatment or anesthesia.
• Dementia or inability to provide adequate follow up.
• Pathologic fractures.
• Open fractures.
• Associated injuries: fracture dislocations, multiple or complex injuries of the ipsilateral limb, complete brachial plexopathy, vascular injury and polytrauma.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 9/7/22. Questions regarding updates should be directed to the study team contact.

• Neurologic Surgery, ENT, plastic surgery, orthopedic surgery, urology resident, fellow and staff surgeons.

• Unable to give informed consent.

• Age ≥ 18 years old (HCC is rare in US children).
• Diagnosis of HCC with cross-sectional imaging or histology.
• 3D MRE of the liver was performed within 1 month of diagnosis.

• History of secondary hepatic malignancy.
• Any medical condition that, in the opinion of the Principal Investigators, would serve as exclusion criteria.

Inclusion Criteria
•Aim 1:

• Patient volunteers, ages ≥ 18 years.
• Having suspicious breast masses scheduled for breast biopsy.
• At least two weeks or more after breast biopsy.

Inclusion Criteria
•Aim 2:

• Patient volunteers, ages ≥ 18 years.
• Suspicious breast masses scheduled for breast biopsy.
• At least two weeks or more after breast biopsy.

Exclusion Criteria
•Aims 1 and 2: 

• Patients with breast implants, mastectomy or any condition that does not allow proper use of U.S.

   

   

   

   

• Women > 35 years old and < 75 years old with at least one of the following:
  • A NCI-BCRAT 5 year risk of ≥ 3% which corresponds to the level in which there is moderate evidence of treatment benefit outweighing risk according to the US Preventative Services Task Force; or
  • IBIS (Tyrer-Cuzik) score for the 10 year risk of breast cancer of ≥ 5%;
  • History of atypical ductal hyperplasia or atypical lobular hyperplasia with a BCRAT ≥ 3% or IBIS ≥ 5%; OR
• Women ≥ 18 years old or ≤ 75 years old with a:
  • BRCA 1 or 2  mutation;
  • CHEK 2;
  • PALB 2;
  • ATM; or
  • Other hereditary breast mutation carrier per investigator; AND
• Able to participate in all aspects of the study.
• Understand and sign the study informed consent. 

• 1. 1.  
• Women whose BCRAT falls below the threshold (< 3% 5 year risk) of moderate benefit according to the US Preventative Task Force AND Women whose IBIS score is < 5% for the 10 year risk.
• Women with known contra-indications to Tamoxifen, raloxifene ,exemestane, or anastrazole.
• Current or prior use of Tamoxifen, raloxifene, exemestane or anastrazole for ≥ 6 months.
• Unable to give informed consent.
• Prior history of invasive breast cancer, ductal carcinoma in situ or other breast cancers.
• History of ovarian cancer within the last 2 years.
• Recurrence of ovarian cancer at any timepoint.
• Prior bilateral  prophylactic mastectomy.
• Women who are currently pregnant.

Eligibility last updated 2/24/22. Questions regarding updates should be directed to the study team contact.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 12/20/22. Questions regarding updates should be directed to the study team contact.

• All national team Nordic Combined and Ski Jumping athletes age 18 and over will be eligible to participate in the study.

• Inability to complete the online questionnaires.

Inclusion Criteria
•Infertility Cohort: 

• Adult females undergoing a euploid frozen embryo transfer.
• Women age 18 years of age or older.
• Must be planning to have all blood work done at Mayo Clinic Rochester so we can receive the study samples.
• Must be planning to deliver within the Mayo Clinic Health System so that we can review pregnancy outcomes.

Exclusion Criteria
•Infertility Cohort: 

• Non English speaking.
• Less than 18 years of age.
• Planning follow-up outside Mayo Clinic Rochester/MCHS.
• Pregnancies with multiple fetuses.

Inclusion Criteria
•Spontaneous Conception Cohort: 

• Adult women presenting with positive pregnancy test to the Obstetrics Department.
• Women age 18 years of age or older.
• Confirmed intrauterine pregnancy (defined as gestational sac with yolk sac +/- fetal pole).
• Patients need to be planning to deliver within the Mayo Clinic Health System so that we can review pregnancy outcomes.

Exclusion Criteria
•Spontaneous Conception Cohort: 

• Non English speaking.
• Less than 18 years of age.
• Planning follow-up outside Mayo Clinic Rochester/MCHS.
• Patients desiring termination of pregnancy.
• Known miscarriage at the time of recruitment.
• Pregnancies with multiples.

• Clinical staff within the Division of Anatomy Pathology- staff pathologists, pathology assistants, transplant surgeons, transplant clinicians, laboratory assistants, reporting specialist, RN coordinators, and other clinical staff.
• Patients who have undergone transplant surgery and have been offered an “interactive conference”, and their family members.

• Clinical staff not involved in transplant surgery.
• Non-transplant patients and their family members.

• All patients ≥ 18 years old.
• With a diagnosis of hematology malignancy.
• Willing and able to provide written informed consent.

• < 18 years old.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 2/21/23. Questions regarding updates should be directed to the study team contact.

• Patient must have cytologically or histologically confirmed solid tumor;
• Age 18 years and above;
• Willingness to undergo venipuncture; and
• Woman known to be pregnant is excluded.

• None.

• Age less than 18 years.
• Present at St. Marys Emergency Department, Mayo Clinic, Rochester, MN.
• The fracture is acute, < 24 hours from time of injury.
• The fracture is of a long bone (radius, ulna, humerus, tibia, fibula or femur).

• Any metabolic, nutritonal or genetic bone disease.
• The patient was taking an opioid within the last 7 days prior to the fracture for any reason.
• Any child who’s fracture is suspected to be due to abuse.
• Any child with a previous or current pain syndrome or “chronic” pain.
• Any child who has static encephalopathy or an altered perception of pain.
• The patients is in foster care, county custody, police custody or currently incarcerated.
• Pregnancy.

Eligibility last updated 6/21/22. Questions regarding updates should be directed to the study team contact.

• Participant must be at least 6 years of age, at the time of signing the informed consent/assent.
• Documented diagnosis of PH, confirmed by genotyping (historically available genotype information is acceptable for study eligibility).
• Participant successfully completed a Dicerna Pharmaceuticals, Inc. study of DCR-PHXC, or is the sibling of a participant who either successfully completed a Dicerna Pharmaceuticals, Inc. study of DCR-PHXC or completed 24 weeks of participation in Study DCR-PHXC-204:
  • For participants rolling over from a multidose study of DCR-PHXC, enrollment should occur within a window of 25 to 75 days from the last dose of study intervention. In order to minimize any gap in administration of DCR-PHXC, every effort should be made to enroll participants as soon as all assessments from the previous study have been completed. It should be noted if the participant was required to repeat the end-of-study (EOS) 24-hour Uox collection for violation of completeness criteria;
  • Siblings must:
  • be younger than 18 years of age;
  • meet all other eligibility criteria (including genotyping) iii. have two 24-hour Uox values ≥ 0.7 mmol (adjusted per 1.73 m^2 BSA) at Screening OR for siblings aged 0 to 5 years old, average spot Uox-to-creatinine ratio at Screening above 2 times the 95th percentile for age based on Matos et al, 1999:
  • 0.44 mol/mol in participants < 6 months;
  • 0.34 mol/mol in participants from 6 months to < 12 months;
  • 0.26 mol/mol in participants 12 months to < 2 years;
  • 0.20 mol/mol in participants from 2 to < 3 years; and
  • 016 mol/mol in participants from 3 to 5 years.
• Participants who perform 24-hour collections must have less than 20% variation between the two 24-hour urinary creatinine excretion values obtained in the screening period. Individuals who do not achieve < 20% variation between the 2 screening values may undergo a second round of urine collection. An extra 7 calendar days may be added to the screening window for participants to complete a second round of urine collection. Should potential participants again fail to achieve the within-20% variation, they will be excluded from participation.
• Estimated GFR at screening ≥ 30 mL/min normalized to 1.73 m^2 BSA, calculated using the CKD-EPI equation in participants aged ≥ 18 years (Levey & Stevens, 2010), or the 2012 multivariate equation by Schwartz in participants aged 6 to 17 years (Schwartz et al., 2012). In Japan, the equation by Uemura et al. will be used for participants aged 6 to 17 years and the equation by Matsuo et al. will be used in participants aged ≥ 18 years (Uemura et al., 2014; Matsuo et al., 2009).
  • Note: For participants rolling over from a 6-month multidose study of DCR-PHXC, the eGFR value from either the Day 150 or Day 180 (EOS) visit may be used for screening.
• Body weight ≥ 10.25 kg for participants rolling over from a previous study of DCR-PHXC OR body weight ≥ 12.75 kg for pediatric siblings.
• A male participant with a female partner of childbearing potential must agree to use contraception, during the treatment period and for at least 12 weeks after the last dose of study intervention and refrain from donating sperm during this period.
• A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: Not a woman of childbearing potential (WOCBP) during the treatment period and for at least 12 weeks after the last dose of study intervention.
• Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
• Participant (and/or participant’s parent or legal guardian if participant is a minor [defined as patient < 18 years of age, or younger than the age of majority, according to local regulations]) is capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol:
  • Adolescents (12 to < 18 years of age, or older than 12 years but younger than the age of majority, according to local regulations) must be able to provide written assent for participation;
  • For children younger than 12 years of age, assent will be based on local regulations.

• Prior renal or hepatic transplantation; or planned transplantation within the study period;
• Currently receiving dialysis.
• Documented evidence of clinical manifestations of systemic oxalosis (including preexisting retinal, heart, or skin calcifications, or history of severe bone pain, pathological fractures, or bone deformations).
• Use of an RNAi drug (other than DCR-PHXC) within the last 6 months 5. History of one or more of the following reactions to an oligonucleotide-based therapy:
  • severe thrombocytopenia (platelet count ≤ 100,000/µL);
  • hepatotoxicity, defined as (alanine aminotransferase [ALT] or aspartate aminotransferase [AST] > 3 × the upper limit of normal [ULN]) and (total bilirubin > 2 × ULN or International Normalized Ratio [INR] > 1.5);
  • severe flu-like symptoms leading to discontinuation of therapy;
  • localized skin reaction from the injection (graded severe) leading to discontinuation of therapy;
  • coagulopathy/clinically significant prolongation of clotting time.
• Participants receiving pyridoxine (vitamin B6) must have been at a stable dose for at least 4 weeks prior to Day 1 and must be willing to remain on the same stable dose throughout the study.
• Participation in any clinical study in which they received an investigational medicinal product (IMP) other than DCR-PHXC within 4 months before Screening:
  • For IMPs (other than DCR-PHXC) with the potential to reduce urine and/or plasma oxalate concentrations, these concentrations must have returned to historical baseline levels prior to Screening.
• Plasma oxalate > 30 µmol/L.
  • Note: For participants > 18 years of age rolling over from a 6-month multidose study of DCR-PHXC, the plasma oxalate value from either the Day 150 or Day 180 (EOS) visit may be used for screening. If the previous study is blinded at the time of entry in DCR-PHXC-301, plasma oxalate values will be reviewed by the unblinded Medical Monitor. For participants ≤ 18 years of age rolling over from a 6-month multidose study of DCR-PHXC, the plasma oxalate value from Screening in the previous study will be used.
• Known hypersensitivity to DCR-PHXC or any of its ingredients.
• Inability or unwillingness to comply with the specified study procedures, including collection of 24-hour urine samples, and the lifestyle considerations.

Eligibility last updated 5/4/22. Questions regarding updates should be directed to the study team contact.

•  ≥ 18 years old.
• Primary diagnosis of spinal stenosis.
• Surgical indication for 1 or 2 level posterior spinal decompression or fusion.

• Previous posterior spinal surgery.
• Systemic corticosteroid use.
• Long-term anticoagulation treatment.
• Diagnosis of diabetes mellitus.
• Diagnosis of peripheral arterial disease.
• Current smoker.
• Active infection of any kind or chronic infection with HIV, Hepatitis C, or Syphilis.